Core Viewpoint - Fosun Pharma reported a decline in revenue but an increase in net profit for Q1 2025, attributed to asset sales and financial asset valuation changes [1][2]. Financial Performance - The company achieved operating revenue of 9.42 billion yuan, a year-on-year decrease of 7.26% [1]. - Net profit attributable to shareholders was 765 million yuan, a year-on-year increase of 25.42 [1]. - The non-recurring net profit was 410 million yuan, a year-on-year decrease of 32.56% [1]. - Net cash flow from operating activities was 1.056 billion yuan, a year-on-year increase of 15.08% [1]. Strategic Developments - Fosun Pharma is actively exiting and integrating non-core assets to optimize its asset structure and accelerate cash flow [2]. - The company received approvals for two innovative drugs during the reporting period: Hetronifly in the EU and a phosphate absorption inhibitor in China [2]. - Fosun Pharma strengthened global licensing collaborations, including agreements with Dr. Reddy's and Sandoz AG for commercialization rights in various regions [2]. Management Changes - The company announced a restructuring of its board, with key leadership changes including Chen Yuqing becoming the new chairman and executive director [3]. - The new leadership will focus on strategic development and talent management [3].